Novel Mechanism of Action for IBD: PALI-2101, their lead drug candidate, employs a unique mechanism by targeting and degrading excess proteases in the gut, offering a distinct approach to managing inflammatory bowel disease (IBD) compared to existing therapies.

Addressing Significant Unmet Medical Need: Palisade Bio focuses on inflammatory bowel disease (IBD), an area with a large patient population where many individuals do not respond adequately to current treatments or experience debilitating side effects, presenting a substantial market opportunity.

Convenient Oral Delivery Platform: Unlike many IBD biologics requiring injections or infusions, PALI-2101 is being developed as an oral capsule, potentially enhancing patient convenience, compliance, and quality of life.